Refine
Has Fulltext
- yes (31)
Is part of the Bibliography
- yes (31)
Year of publication
- 2021 (31) (remove)
Document Type
- Journal article (28)
- Doctoral Thesis (3)
Keywords
- positron emission tomography (4)
- CXCR4 (3)
- dosimetry (3)
- prostate cancer (3)
- 53BP1 (2)
- MRI (2)
- NET (2)
- PET (2)
- biokinetics (2)
- biomarkers (2)
- molecular imaging (2)
- theranostics (2)
- 177Lu SPECT/CT imaging (1)
- 3D printing (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- Alzheimer’s disease (1)
- BON-1 (1)
- BSS directive (1)
- CTNNB1 (1)
- CYP11B enzymes (1)
- Cushing’s disease (1)
- Cushing’s syndrome (1)
- DNA Damage Repair (1)
- DNA damage (1)
- DOTA-EB-TATE (1)
- ECG-gated PET (1)
- FAP (1)
- FAPI PET/CT (1)
- FDG (1)
- FDG PET/CT (1)
- GCA (1)
- Gallium-68 Pentixafor (1)
- HFpEF (1)
- In vitro (1)
- LMI1195 (1)
- MIBG scintigraphy (1)
- MS-18 (1)
- Matlab (1)
- Multiples Myelom (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NR3C1 (1)
- PET/CT (1)
- PMR (1)
- PSMA (1)
- Parkinson's disease (1)
- Plasmozytom (1)
- Positronen-Emissions-Tomografie (1)
- Primary hyperparathyroidism (pHPT) (1)
- QGP-1 (1)
- Radioiodine Therapy (1)
- Ratte (1)
- Theranostik (1)
- USP8 (1)
- Uptake-1 (1)
- Waldeyer’s tonsillar ring (1)
- Wnt (1)
- [18F]FDG PET/CT (1)
- [18F]FDG-PET-CT (1)
- [\(^{223}\)Ra]RaCl\(_{2}\) (1)
- [\(^{68}\)Ga] Pentixafor (1)
- abdominal lymph node metastases (1)
- adrenal incidentaloma (1)
- adrenocortical carcinoma (1)
- amyloid-β (Aβ) (1)
- biodosimetry (1)
- butyrylcholinesterase (1)
- cancer associated fibroblasts (1)
- cancer of unknown primary (CUP) (1)
- cancer-associated fibroblast (1)
- carbamate (1)
- data analysis (1)
- diabetic cardiomyopathy (1)
- diagnostics (1)
- diastolic dysfunction (1)
- drug discovery (1)
- ejection fraction (1)
- enzyme kinetics (1)
- evans blue (1)
- fibroblast activation protein (1)
- fluorine-18 (1)
- giant cell arteritis (1)
- glomerular filtration rate (1)
- glucocorticoid excess (1)
- harmonization of SPECT/CT imaging (1)
- head and neck cancer (1)
- hypercortisolism (1)
- imaging (1)
- immune check inhibitor (1)
- inflammation (1)
- international multicenter comparison exercise (1)
- intraindividual comparison (1)
- kidney (1)
- left-ventricular function (1)
- meningioma (1)
- molecular diagnostics (1)
- molecular medicine (1)
- molecular radiotherapy (MRT) (1)
- multiple system atrophy (1)
- nephrology (1)
- neuroblastoma (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumor (1)
- neuroendocrine tumors (NET) (1)
- nitrate and thyroid carcinogenesis (1)
- norepinephrine transporter (1)
- nuclear medicine (1)
- nuclear medicine therapy (1)
- optimization (1)
- parathyroid carcinoma (1)
- pediatric thyroid cancer after Chernobyl and Fukushima (1)
- pembrolizumab (1)
- peripheral nervous system (1)
- phantom (1)
- polymyalgia rheumatica (1)
- positron emission tomography/computed tomography (1)
- preclinical PET (1)
- preclinical imaging (1)
- preoperative localization (1)
- prostate-specific membrane antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- quantitative SPECT/CT (1)
- radiobiology (1)
- radioligand therapy (1)
- radionuclide therapy (1)
- radiopharmaceuticals (1)
- radiotracers (1)
- renal (1)
- renal function (1)
- repeat surgery (1)
- repeated surgery (1)
- reporting and data system (1)
- rising incidence of thyroid cancer (1)
- screening and overdiagnosis (1)
- skin biopsy (1)
- somatostatin receptor (1)
- somatostatin receptor (SSTR) (1)
- standardization of SPECT/CT imaging (1)
- stem cells (1)
- stem-cell research (1)
- traceability of SPECT/CT imaging (1)
- urology (1)
- various cancer diseases (1)
- vasculature (1)
- vasculitis (1)
- α-Emitter (1)
- β-catenin (1)
- γ-H2AX (1)
- γ-h2ax (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (31) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 755523 (1)
Purpose
One therapy option for prostate cancer patients with bone metastases is the use of [\(^{223}\)Ra]RaCl\(_{2}\). The α-emitter \(^{223}\)Ra creates DNA damage tracks along α-particle trajectories (α-tracks) in exposed cells that can be revealed by immunofluorescent staining of γ-H2AX+53BP1 DNA double-strand break markers. We investigated the time- and absorbed dose-dependency of the number of α-tracks in peripheral blood mononuclear cells (PBMCs) of patients undergoing their first therapy with [\(^{223}\)Ra]RaCl\(_{2}\).
Methods
Multiple blood samples from nine prostate cancer patients were collected before and after administration of [\(^{223}\)Ra]RaCl\(_{2}\), up to 4 weeks after treatment. γ-H2AX- and 53BP1-positive α-tracks were microscopically quantified in isolated and immuno-stained PBMCs.
Results
The absorbed doses to the blood were less than 6 mGy up to 4 h after administration and maximally 16 mGy in total. Up to 4 h after administration, the α-track frequency was significantly increased relative to baseline and correlated with the absorbed dose to the blood in the dose range < 3 mGy. In most of the late samples (24 h - 4 weeks after administration), the α-track frequency remained elevated.
Conclusion
The γ-H2AX+53BP1 assay is a potent method for detection of α-particle-induced DNA damages during treatment with or after accidental incorporation of radionuclides even at low absorbed doses. It may serve as a biomarker discriminating α- from β-emitters based on damage geometry.